Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients

Massimo Martino, Alberto Bottini, Giovanni Rosti, Daniele Generali, Simona Secondino, Sandro Barni, Roberto Maisano, Francesco Lanza, Luca Castagna, Paolo Pedrazzoli

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell transplantation (AHPCT) for high-risk (HR) or metastatic breast cancer (MBC) is no longer an option. Areas covered: An expert panel including medical oncologists and hematologists produce an opinion paper on the use of HDC and AHPCT in BC patients and they explain why they believe that; despite inconclusive results thus far, this treatment should have an ongoing role in breast cancer management under clinical trials. Expert opinion: HDC with AHPCT has become a safe treatment modality and an advantage in disease-free survival has been observed in most of the studies with HDC, with the caveat that today, even a limited relapse-free survival and progression-free survival benefit is sufficient for the approval of new antineoplastic agents. Moreover, in HRBC, an overall survival benefit by HDC could be achieved in the HER2-ve and triple-negative populations and, in this setting, HDC with AHPCT represents a therapeutic option that can be proposed to well-informed patients. In MBC, the HDC approach should be investigated further in selected patients with HER2-ve, chemosensitive disease. This paper is not intended to give any conclusion, but rather to open a debate on the value of HDC in HR and MBC.

Original languageEnglish
Pages (from-to)1505-1515
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume12
Issue number11
DOIs
Publication statusPublished - 2012

Keywords

  • Autologous hematopoietic progenitor cell transplantation
  • High-dose chemotherapy
  • High-risk breast cancer
  • Metastatic breast cancer

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery
  • Medicine(all)

Fingerprint Dive into the research topics of 'Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients'. Together they form a unique fingerprint.

Cite this